rs10482605 — NR3C1

NR3C1 promoter variant reducing glucocorticoid receptor transcription; G allele (coding-strand C) associated with blunted GR expression and 4.7-fold increased risk of metabolic syndrome when homozygous

See your personal result for NR3C1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Glucocorticoid Receptor Promoter — How NR3C1 rs10482605 Dims the Stress Response and Raises Metabolic Risk

Cortisol, the body's primary stress hormone, communicates with cells through the glucocorticoid receptor (GR) encoded by NR3C1. When cortisol binds the GR, it triggers gene expression programs that regulate inflammation, blood glucose, immune function, and fat distribution — all processes central to both metabolic health and the biology of aging. The rs10482605 variant sits in the promoter region of NR3C1, upstream of the coding sequence, where it influences how much GR protein the cell produces in the first place. Less GR means weaker cortisol signaling — a subtle but persistent dampening of the hormone's metabolic and anti-inflammatory effects that compounds over a lifetime.

Two findings from independent research programs define this SNP's clinical significance. First, Kumsta et al. (2009)11 Kumsta et al. (2009)
Kumsta R et al. Characterization of a glucocorticoid receptor gene (GR, NR3C1) promoter polymorphism reveals functionality and extends a haplotype with putative clinical relevance. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(4):476-82 demonstrated in reporter gene assays that the risk allele reduces GR transcriptional activity in brain-derived cell lines under both basal and stimulated conditions — making this a functionally characterized regulatory variant, not merely an association signal. Second, Kolb et al. (2023)22 Kolb et al. (2023)
Kolb KL et al. Glucocorticoid Receptor Gene (NR3C1) Polymorphisms and Metabolic Syndrome: Insights from the Mennonite Population. Genes (Basel). 2023;14(9):1805 found that homozygotes for the risk allele had a 4.74-fold increased odds of metabolic syndrome — a finding that places this promoter variant in direct conversation with the global epidemic of insulin resistance, central obesity, hypertension, and dyslipidemia.

The Mechanism

rs10482605 is located at chromosome 5, position 143,403,956 (GRCh38), within the promoter region of NR3C1. Because NR3C1 spans the minus strand of chromosome 5, the alleles described in published papers use coding-strand notation: the T allele (coding strand) corresponds to the A allele on the plus strand (reference, major), and the C allele (coding strand) corresponds to the G allele on the plus strand (alternate, minor). Genome files report plus-strand alleles, so the risk allele in this database is G (plus strand, ~32% global frequency).

The NR3C1 gene uses multiple alternative first exons — nine non-coding exons (1A, 1B, 1C, 1D, 1E, 1F, 1H, 1I, 1J) that permit tissue-specific and stimulus-specific control of GR expression. The rs10482605 position maps to a CpG island33 CpG island
A stretch of DNA where CpG dinucleotides are present at higher than expected frequency — CpG islands in gene promoters often regulate transcriptional activity and are sensitive to methylation-based silencing in the 5'UTR region. The G (risk) allele alters the sequence within this regulatory context, reducing the transcriptional drive on GR expression. In reporter assays, this reduction in activity was observed under both resting and stimulated conditions, suggesting a constitutive dampening of GR production rather than a context-specific effect.

The variant sits in high linkage disequilibrium44 linkage disequilibrium
LD means two variants are inherited together more often than chance would predict — when one is present, the other tends to be too with rs6198, the 9β variant in NR3C1's 3'UTR that stabilizes the glucocorticoid-resistant GRβ mRNA isoform. This creates a double-hit haplotype: the G allele at rs10482605 reduces GR transcription at the promoter, while the co-occurring C allele at rs6198 shifts the expressed mRNA toward the dominant-negative GRβ isoform. The net result is less GR protein being produced, and a larger fraction of what is produced being the cortisol-resistant form — a compounding attenuation of glucocorticoid signaling.

The Evidence

Kumsta et al. (2009) genotyped 219 subjects and performed in vitro reporter gene assays to establish that rs10482605 is a functional variant. The functional evidence — reduced transcriptional activity in the risk allele — is the foundation for understanding why this SNP matters biologically. The observation of high LD with rs6198 extended the known NR3C1 haplotype architecture and proposed a mechanism for depression risk: blunted GR expression reduces negative feedback on the HPA axis, permitting prolonged cortisol elevation under stress.

The metabolic syndrome connection was established by Kolb et al. (2023) in a genetically isolated Brazilian Mennonite community — a founder population with reduced genetic background noise. The study genotyped 74 MetS cases and 138 unaffected controls (212 total), plus a replication set of 236 individuals. Homozygosity for the risk allele (G/G on plus strand; C/C on coding strand) was associated with OR = 4.74 (95% CI 1.10–20.28, pcorr = 0.024). An independent haplotype analysis confirmed this signal (TTCGTTGATT haplotype, OR = 4.74, pcorr = 0.048). Critically, the association was independent of age, physical activity, and family environment — pointing to a direct genetic contribution to metabolic risk rather than a lifestyle confounder.

The evidence level is rated moderate: the functional characterization (Kumsta 2009) is solid, and the metabolic syndrome OR of 4.74 is large. However, the metabolic finding comes from a single study in a founder population (which both boosts power and limits generalizability), and cross-population replication is not yet established. The mechanistic link between reduced GR expression and metabolic syndrome — while biologically plausible — is not directly demonstrated in the Mennonite study.

The biological pathway is well-supported: chronic GR insufficiency impairs the normal glucocorticoid suppression of inflammatory cytokines, and chronic low-grade inflammation is a driver of insulin resistance, central fat deposition, and dyslipidemia — the cardinal features of metabolic syndrome. Furthermore, GR-mediated transcriptional regulation of hepatic lipid metabolism genes55 GR-mediated transcriptional regulation of hepatic lipid metabolism genes
The GR directly regulates PCSK9, BHLHE40, and SREBP-2 pathway genes in liver cells, meaning altered GR activity can independently shift cholesterol and triglyceride metabolism provides an additional route by which reduced GR transcription could produce dyslipidemia.

Practical Implications

For homozygous GG carriers (~10% of the population globally), the combination of reduced GR transcriptional activity and the metabolic syndrome risk signal warrants proactive metabolic monitoring. The actionable targets are the five components of metabolic syndrome: waist circumference, fasting glucose, blood pressure, triglycerides, and HDL cholesterol. GG carriers who develop metabolic syndrome may have a component that is driven by impaired glucocorticoid signaling — meaning that lifestyle interventions need to account for the possibility that standard inflammatory and metabolic setpoints are shifted at the receptor level.

For AG heterozygotes (~44% of the population), the functional reduction in GR expression is partial. The metabolic syndrome OR in heterozygotes is not separately reported in the available literature, but given the additive inheritance pattern of most GR variants, a graded effect is likely. Heterozygotes benefit from metabolic awareness without the same urgency as GG homozygotes.

For AA homozygotes (~46%), full GR promoter activity is maintained. This genotype represents the ancestral configuration with no identified metabolic risk from this specific locus.

Interactions

rs10482605 is in high linkage disequilibrium with rs6198 (9β)66 rs6198 (9β), the NR3C1 3'UTR variant that stabilizes GRβ mRNA and blunts glucocorticoid sensitivity. When both risk alleles are present on the same haplotype, the individual faces both reduced GR transcription (rs10482605 G) and a shift toward the dominant-negative GRβ isoform (rs6198 C). This compound haplotype was the original focus of Kumsta et al. (2009) and likely represents the maximum NR3C1-driven glucocorticoid resistance achievable from coding and promoter variation in this gene.

Within the same NR3C1 gene, two longevity-associated intronic variants are already catalogued: rs296315477 rs2963154 and rs1051552288 rs10515522, both from the Polish centenarian cohort. Those variants associate with survival to extreme old age and altered cholesterol metabolism through GR-driven hepatic lipid regulation. rs10482605 adds the metabolic syndrome dimension — showing that the same gene's promoter regulation influences metabolic risk decades before extreme longevity outcomes become observable.

The BclI variant rs4142324799 BclI variant rs41423247 sits on the same gene and increases GR sensitivity. Combined NR3C1 haplotype analysis — incorporating rs10482605 (promoter activity), rs6198 (GRβ isoform balance), and rs41423247 (receptor sensitivity) — represents the most comprehensive picture of an individual's glucocorticoid receptor biology. No single-study haplotype analysis covering all four variants has been published, but the mechanistic logic supports composite profiling.

Genotype Interpretations

What each possible genotype means for this variant.

AA Full Promoter Activity Normal

Common genotype with full NR3C1 promoter activity — no metabolic syndrome risk from this locus

You carry two copies of the A allele at rs10482605 (plus-strand notation), corresponding to the T allele in coding-strand descriptions. This is the major genotype, present in approximately 46% of people globally. It is associated with full NR3C1 promoter transcriptional activity — meaning your glucocorticoid receptor gene is expressed at its baseline level from this regulatory position.

In the Brazilian Mennonite study identifying metabolic syndrome risk, the AA genotype was the reference category — no elevated metabolic syndrome risk was associated with this configuration. Your NR3C1 biology at this locus supports normal cortisol signaling via the glucocorticoid receptor.

AG Reduced Promoter Activity Intermediate

One copy of the G risk allele — partial reduction in NR3C1 promoter activity

You carry one copy of the G risk allele (plus-strand notation; corresponds to the C allele in coding-strand descriptions used in published papers). This heterozygous configuration is present in roughly 44% of people globally, making it the most common genotype at this locus. Functional studies show that the G allele reduces NR3C1 transcriptional activity in vitro, so one copy partially dampens the glucocorticoid receptor's expression relative to the AA genotype.

The metabolic syndrome risk reported in the Mennonite study was for GG homozygotes (OR = 4.74); heterozygote-specific risk was not separately quantified. Given the additive nature of regulatory variants, a moderate graded effect in AG carriers is biologically plausible. This SNP is also in high LD with rs6198 (9β), so if you also carry the rs6198 C risk allele, the two variants together create a haplotype associated with blunted glucocorticoid signaling and stress-disorder vulnerability.

GG Promoter Downregulated High Risk

Two copies of the G risk allele — substantially reduced NR3C1 expression and 4.7-fold increased metabolic syndrome risk

The two functional consequences of the GG genotype operate at different levels of NR3C1 biology. At the promoter, the G allele reduces how much GR mRNA is transcribed, meaning fewer receptor molecules are available to bind cortisol. Because this SNP is in high LD with rs6198 (9β), GG homozygotes also frequently carry the rs6198 C allele that stabilizes GRβ (dominant-negative isoform) mRNA. The combined effect is both less total GR protein and a higher fraction of the glucocorticoid-resistant GRβ form.

Metabolic syndrome involves five interconnected components: central obesity, elevated fasting glucose, hypertension, elevated triglycerides, and low HDL cholesterol. Impaired GR signaling can contribute to all five: reduced GR-mediated GLUT4 expression impairs glucose uptake; reduced anti-inflammatory GR activity allows adipose-derived IL-6 and TNF-α to drive insulin resistance; hepatic GR dysregulation shifts VLDL and HDL metabolism.

The Mennonite study found the metabolic association was independent of physical activity and family environment — pointing to a direct genetic contribution rather than a lifestyle mediated effect. However, the study was conducted in a founder population with genetic homogeneity that can amplify effect sizes, so the true OR in the general population may be smaller than 4.74. The functional evidence from Kumsta 2009 provides mechanistic support that makes the metabolic finding biologically credible.

The GG genotype also sits within the haplotype context of the TTCGTTGATT haplotype — a 10-SNP block spanning the NR3C1 5'UTR and promoter region — in which the rs10482605*C (G plus-strand) allele is exclusively found. This haplotype association (OR = 4.74, pcorr = 0.048) reinforces the single-SNP finding and implies that rs10482605 is the key functional variant within this haplotype block.